Please login to the form below

Not currently logged in
Email:
Password:

infliximab

This page shows the latest infliximab news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

Sandoz’Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Latest news

More from news
Approximately 15 fully matching, plus 136 partially matching documents found.

Latest Intelligence

  • The tipping point The tipping point

    For example, since 2015, when the first monoclonal antibody biosimilar, infliximab, was launched in Europe we have seen a notable increase in the overall use of infliximab. ... Driving disparity. If we look across Europe at biosimilar penetration, even

  • Building a bright future Building a bright future

    We have many examples where small molecule and biosimilars have improved uptake such as the case of infliximab in Norway, which was supported by the government that sponsored clinical trials showing

  • The reality of real-world evidence The reality of real-world evidence

    RWE data presented at ECCO this year showed that switching to the biosimilar Remsima (infliximab) from the originator had no negative effect on safety and efficacy in 10 real-world studies.

  • Deal Watch October 2016 Deal Watch October 2016

    For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab. ... The FDA accepted the Biologics Licence Application for infliximab in May and etanercept has been approved in Canada.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    These were led by the launch in February of the first biosimilar versions of Remicade (infliximab). ... Certainly when it comes to early experiences of the new infliximab biosimilars their price point looms large, according to Laurent Chanroux, associate

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Biosimilars: Getting the flock to market

    brands. Typically they are priced at a discount of 10-30%, and some infliximab biosimilars offer reductions of up to 60%. ... Last year an audit by the Royal College of Physicians showed that Remicade (infliximab) biosimilars were "safe, effective and

  • Infographic: RA Perceptions

    Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small.

  • Innovation in pharma: the highs and lows of the current healthcare economy

    So far, the introduction of biosimilar medicines seems to be progressing at a pace (uptake of the biosimilar infliximab was at a national average of 79.7% earlier this year), but

  • The Biosimilar Challenge

    Positive experience of using infliximab biosimilars in gastro infusion clinics has had a big impact on the overall confidence of biosimilars. ... However, positive experience of switching in other therapy areas especially gastro patients receiving

  • Biosimilars: Getting the flock to market

    brands. Typically they are priced at a discount of 10-30%, and some infliximab biosimilars offer reductions of up to 60%. ... Last year an audit by the Royal College of Physicians showed that Remicade (infliximab) biosimilars were "safe, effective and

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics